Table 3 Percentage distribution of patients with evaluable data for analysis in clinically significant categories of EuroQoL health status index (EQ-5D) by treatment group

PRO measure	ETN (n = 142) (%)	ETN+MTX (n = 141) (%)	Difference between treatment groups (95% CI*)†
EQ-5D utility improvement ⩾0.05	62.9	66.8	−3.9 (−7.01, 15.09)
EQ-5D VAS >82 at week 16	30.32	29.55	0.76 (−9.37,10.9)

ETN, etanercept (25 mg twice weekly); MTX, methotrexate (⩾12.5 mg/week); EQ-5D, EuroQoL five-dimensional assessment of current health state; VAS: visual analogue scale.
*CI was calculated by binomial distribution. †Values were not significantly different between treatment groups.